Published in J Immunother on February 10, 2004
TLR-based immune adjuvants. Vaccine (2010) 2.10
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 1.39
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
Adjuvant therapy for melanoma. Cancer J (2012) 1.01
B cell TLRs and induction of immunoglobulin class-switch DNA recombination. Front Biosci (Landmark Ed) (2012) 0.99
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol (2012) 0.94
Immunotherapy of head and neck cancer: current and future considerations. J Oncol (2009) 0.93
Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses. PLoS One (2014) 0.85
Toll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes. Sci Rep (2013) 0.82
Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E. Oncotarget (2015) 0.82
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. Cancer Immunol Immunother (2015) 0.81
Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol (2016) 0.80
Vaccine Potentiation by Combination Adjuvants. Vaccines (Basel) (2014) 0.80
Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival. Clin Cancer Res (2015) 0.79
Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78
A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors. J Immunother (2015) 0.78
MAGE-A antigens in patients with primary oral squamous cell carcinoma. Clin Oral Investig (2009) 0.77
Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit. Oncotarget (2015) 0.76
Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat Commun (2016) 0.75
Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects. PLoS One (2013) 0.75
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). Ann Oncol (2016) 0.75
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol (2003) 2.83
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Molecular profiling of platinum resistant ovarian cancer. Int J Cancer (2006) 2.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood (2004) 2.08
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol (2002) 1.99
Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol (2006) 1.88
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Functional CCR9 expression is associated with small intestinal metastasis. J Invest Dermatol (2004) 1.80
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res (2003) 1.67
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood (2002) 1.62
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood (2005) 1.58
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol (2006) 1.56
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med (2006) 1.51
Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol Ther (2006) 1.50
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res (2010) 1.44
Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics (2008) 1.44
Side effects of interferon-alpha therapy. Pharm World Sci (2005) 1.41
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res (2004) 1.39
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer (2009) 1.36
Natural T cell immunity against cancer. Clin Cancer Res (2003) 1.36
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshop. Stand Genomic Sci (2010) 1.35
Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine (2005) 1.30
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer (2004) 1.29
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (2011) 1.28
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res (2002) 1.22
The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer (2009) 1.22
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood (2006) 1.18
The impact of harmonization on ELISPOT assay performance. Methods Mol Biol (2012) 1.18
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med (2011) 1.15
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer (2009) 1.15
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res (2009) 1.14
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev (2002) 1.13
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res (2003) 1.12
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A (2013) 1.11
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology (2009) 1.10
CMV-specific central memory T cells reside in bone marrow. Eur J Immunol (2007) 1.08
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer (2008) 1.07
Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer (2006) 1.07
Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg (2008) 1.07
The potential of statins as part of anti-cancer treatment. Eur J Cancer (2005) 1.07
Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol (2003) 1.06
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood (2011) 1.06
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol (2012) 1.05
Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol (2003) 1.04
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res (2007) 1.04
Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res (2011) 1.04
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res (2002) 1.03
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother (2004) 1.03
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med (2011) 1.02
Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol (2008) 1.02
Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol (2008) 1.01
Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations. J Transl Med (2008) 1.01
Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité. Anticancer Res (2009) 1.00
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother (2015) 0.99
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res (2007) 0.99
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother (2009) 0.99
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood (2012) 0.99
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother (2012) 0.98
Immunological monitoring of cancer vaccine therapy. Expert Opin Biol Ther (2004) 0.97
Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer (2003) 0.97
Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer (2006) 0.97
Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol (2003) 0.97
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res (2005) 0.96
IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother (2003) 0.96
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res (2008) 0.96
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res (2008) 0.95
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood (2006) 0.95
Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges (2008) 0.94
Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol (2005) 0.94
Treatment of melanoma. Dtsch Arztebl Int (2008) 0.93
T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med (2005) 0.92